Haemonetics (HAE) said it updated its financial reporting structure and will transition to two reportable segments from three starting in the first quarter of fiscal 2027.
Under the new structure, the plasma and blood center segments will be combined into a single reportable segment called Apheresis, while the hospital segment will be renamed MedSurg.
Haemonetics said the Apheresis segment will include supplemental disclosure for plasma and other operations.
The MedSurg segment will continue to include Haemonetics' blood management technologies and interventional technologies businesses, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.